Pfizer Inc. ($PFE) Earnings (Q1 FY22)

 Pfizer Inc. ($PFE) Earnings and Opinion:


Pfizer is a company in the Healthcare sector and operates in the Drug Manufacturers-General industry. The company develops and sells biopharmaceutical products worldwide. The company was originally founded in 1849 and is currently headquartered in New York, New York. Pfizer was originally put on the stock market in 1942.

Pfizer EPS and Revenue (Q1 FY22)

  • EPS of $1.62 beating expectations of $1.57
  • Revenue of $25.66B beating expectations of $24.73B
Pfizer Q1 Financial Highlights:
  • 82% Operational growth
  • 77% increase in revenues
  • Net income of $7.9B, up 61% (YOY)
  • 72% increase in EPS
Opinion:
Pfizer is currently moving higher after reporting an impressive earnings report this morning. The company had strong performance in the Covid-19 vaccine segment. The vaccine numbers will probably be heavy in the beginning of this year, but wear off towards the end. Companies like Pfizer and Moderna have been really able to thrive in the pandemic. They were the companies that seemingly came up with the most effective vaccines to treat Covid, and they did it at a frantic pace. Both companies are still trying to work more and more to bring out new vaccines and vaccines that the kids can take for the disease. They are really reliant on these covid vaccine sales though, which in turn could bite them in the butt starting in the next few quarters. These companies are solid companies, but they need to develop more and more continuous products, instead of relying too much on this one time vaccine. I personally do not have any holdings in this company and do not plan on purchasing any. These biopharma stocks are really hard to predict, unless you know the medical field well enough. I like to invest my money elsewhere and in companies that I have a little bit more knowledge in.

*Information from Pfizer, Yahoo Finance, Google

Comments

Popular posts from this blog

Weekly Earnings Review: September 25, 2023- September 29, 2023

Weekly Earnings Review: October 16, 2023- October 20, 2023

Weekly Earnings Review: November 27, 2023- December 1, 2023